KP
Zoetis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| APOQUEL (oclacitinib) | Canine atopic dermatitis | Commercial |
| CYTOPOINT (lokivetmab) | Canine atopic dermatitis | Commercial |
| Revolution Plus | Feline parasiticides | Commercial |
| Draxxin | Bovine respiratory disease | Commercial |
| Suvaxyn PCV | Porcine circovirus | Commercial |
| Vanguard Plus 5 | Canine core vaccines | Commercial |
| STRONGHOLD Plus | Feline parasiticides | Commercial |
Leadership Team at Zoetis
WJ
Wetteny Joseph
Chief Financial Officer
RL
Roxanne Lagano
Executive Vice President and Chief Digital & Technology Officer
RT
Roman Trawicki
Group President, International
TY
Todd Young
Group President, U.S. Operations
HC
Heidi Chen
Executive Vice President, Chief Legal Officer and Corporate Secretary
GD
Glenn David
Executive Vice President, Chief Human Resources Officer